Is TERN-601 legal in Australia?

Dose-dependent weight loss in phase 1 and phase 2, then discontinued after three participants developed liver enzyme elevations consistent with potential drug-induced liver injury.

The second oral small-molecule GLP-1 agonist in this batch to work and be stopped, and its report is unusually clear about why. Phase 1 ran 28 days and produced dose-dependent weight loss with statistically significant reductions against placebo at every dose, along with the pharmacodynamic signatures you would expect from this class: reduced appetite and delayed gastric emptying.

Mechanism: An orally administered small-molecule agonist at the GLP-1 receptor, dosed once daily. Small molecules bind the receptor differently from the native peptide because they cannot reproduce its large binding surface, but the downstream signalling is the same: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and reduced appetite.

Regulatory history: Never approved. Clinical development was discontinued following liver safety findings in phase 2.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for TERN-601 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.